A Randomized, Controlled Trial of the Novel, Potent Kv7 Channel Opener Azetukalner in Individuals with Major Depressive Disorder and Anhedonia: Neural Response to Reward, Clinical Outcomes, and Safety
Authors:
- James MurroughJames Murrough
- Philipp NeukamPNPhilipp Neukam
- Usha GovindarajuluUGUsha Govindarajulu
- Jessica AblesJAJessica Ables
- Sara HameedSHSara Hameed
- Marcella CorwinMCMarcella Corwin
- Mackenzie HargroveMHMackenzie Hargrove
- Helena ChangHCHelena Chang
- Sarah BoukezziSBSarah Boukezzi
- Chris KellyCKChris Kelly
- Alan SwannASAlan Swann
Preprint
- 15 September 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
Major Depressive Disorder (MDD) is a common and debilitating disease. Kv7 potassium channels are relevant to reward processing and represent a novel target for depression and anhedonia. Azetukalner is a positive allosteric modulator of Kv7. This phase II, randomized, double-blind, placebo-controlled trial assessed changes in brain reward function, clinical outcomes, and safety following treatment with azetukalner or placebo in individuals with MDD and anhedonia. The study included 60 participants with MDD and anhedonia in a current major depressive episode. Participants were randomized 1:1 to receive azetukalner (20 mg orally once daily with food) or placebo for 8 weeks. The primary endpoint was change in bilateral ventral striatum (VS) activity assessed by fMRI during a reward task from baseline to week 8. Secondary endpoints included changes in depression severity and anhedonia measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) and Snaith-Hamilton Pleasure Scale (SHAPS). Of 60 participants, 29 were randomized to azetukalner and 31 to placebo. There was no significant difference in VS response to reward anticipation between groups. Compared to placebo, azetukalner was associated with numerical benefit on the MADRS and SHAPS that did not reach statistical significance. Additional exploratory endpoints also favored azetukalner over placebo. Discontinuation rates due to adverse events were low and did not differ across groups. Despite not meeting the primary neuroimaging endpoint,secondary and exploratory outcomes suggested potential improvement in depressive and anhedonia symptoms, consistent with recent studies. Trial Registration: Clinicaltrials.gov ID NCT04827901Keywords
All Related Versions
This publication has 24 references indexed in Scilit:
- Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive DisorderJAMA Network Open, 2025
- The role of KCNQ channel activators in management of major depressive disorderJournal of Affective Disorders, 2024
- Ventral tegmental area integrity measured with high-resolution 7-Tesla MRI relates to motivation across depression and anxiety diagnosesNeuroImage, 2022
- In vitro and in vivo characterization of Lu AA41178: A novel, brain penetrant, pan-selective Kv7 potassium channel opener with efficacy in preclinical models of epileptic seizures and psychiatric disordersEuropean Journal of Pharmacology, 2020
- The role of fMRI in drug developmentDrug Discovery Today, 2018
- Hyperactive Error Responses and Altered Connectivity in Ventromedial and Frontoinsular Cortices in Obsessive-Compulsive DisorderBiological Psychiatry, 2011
- Reduced hedonic capacity in major depressive disorder: Evidence from a probabilistic reward taskJournal of Psychiatric Research, 2008
- Molecular Adaptations Underlying Susceptibility and Resistance to Social Defeat in Brain Reward RegionsCell, 2007
- Anticipatory and consummatory components of the experience of pleasure: A scale development studyJournal of Research in Personality, 2006
- Toward an objective characterization of an anhedonic phenotype: A signal-detection approachBiological Psychiatry, 2005